Revised Financial Results for the Quarter Ended 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals reported strong Q2 FY26 results with net sales rising to Rs 14,358.53 lakhs, up about 34% from Rs 10,689.19 lakhs in Q2 FY25. Half-yearly net sales grew nearly 43% to Rs 26,298.82 lakhs versus Rs 18,442.77 lakhs a year ago. Profit after tax nearly doubled to Rs 1,649.81 lakhs in H1 FY26 from Rs 840.32 lakhs in H1 FY25, while Q2 PAT jumped to Rs 973.23 lakhs from Rs 427.33 lakhs. Basic EPS for the half-year stood at Rs 34.94 (vs Rs 17.80). Operating cash flow turned positive at Rs 866.87 lakhs in H1 FY26, compared to a negative Rs 5,640.73 lakhs in H1 FY25. The auditor, R.H. Nisar & Co., issued an unmodified limited review conclusion on both standalone and consolidated results.
The sharp revenue and profit growth, along with margin expansion and a turnaround in operating cash flow, signal a strong operating quarter for shareholders. However, finance costs and employee costs have risen significantly, and overall borrowings remain elevated, so investors should watch for sustained margin discipline in coming quarters.